血清阳性对生物抗风湿药物治疗效果的影响:16个注册中心的协作研究
结果显示血清阳性与药物停药的关联因药物而异,与TNFis无显著关联,与TCZ、ABA和RTX的停药风险降低相关,且疗效差异呈现相同模式,RTX差异最大。
要点
- 血清阳性与RTX和ABA的停药风险降低及疗效改善相关
- 血清阳性与TNFis的停药和疗效无显著关联
- 血清阳性与TCZ的关联较小,疗效差异亦较小
核心结论
- 血清阳性与non-TNFi bDMARDs(尤其是RTX和ABA)的疗效增加相关,但与TNFis无关。
主要发现
- 血清阳性与药物停药的关联因bDMARDs而异(交互作用P<0.001)。
- 调整后风险比(血清阳性 vs 血清阴性):TNFis 1.01(95%CI 0.95, 1.07);TCZ 0.89(0.78, 1.02);ABA 0.80(0.72, 0.88);RTX 0.70(0.59, 0.84)。
- 缓解和低疾病活动度率的调整差异呈现相同模式:TNFis无差异,TCZ差异小,ABA差异较大,RTX差异最大(Lundex缓解差异+5.9%,低疾病活动度差异+11.6%)。
关键数值与推荐
- 血清阳性定义为RF和/或ACPA阳性。
- 停药分析采用Cox回归,调整合并及既往治疗、患者和疾病特征、国家和日历年。
- 疗效分析采用临床疾病活动指数(CDAI)随时间的变化。
临床怎么用
- 在RA患者选择bDMARDs时,血清阳性状态可支持优先考虑RTX或ABA而非TNFis。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: RF and ACPA are used as diagnostic tools and their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation and effectiveness of bDMARDs in patients with RA, using head-to-head comparisons in a real-world setting. METHODS: We conducted a pooled analysis of 16 observational RA registries. Inclusion criteria were a diagnosis of RA, initiation of treatment with rituximab (RTX), abatacept (ABA), tocilizumab (TCZ) or TNF inhibitors (TNFis) and available information on RF and/or ACPA status. Drug discontinuation was analysed using Cox regression, including drug, seropositivity, their interaction, adjusting for concomitant and past treatments and patient and disease characteristics and accounting for country and calendar year of bDMARD initiation. Effectiveness was analysed using the Clinical Disease Activity Index evolution over time. RESULTS: Among the 27 583 eligible patients, the association of seropositivity with drug discontinuation differed across bDMARDs (P for interaction <0.001). The adjusted hazard ratios for seropositive compared with seronegative patients were 1.01 (95% CI 0.95, 1.07) for TNFis, 0.89 (0.78, 1.02)] for TCZ, 0.80 (0.72, 0.88) for ABA and 0.70 (0.59, 0.84) for RTX. Adjusted differences in remission and low disease activity rates between seropositive and seronegative patients followed the same pattern, with no difference in TNFis, a small difference in TCZ, a larger difference in ABA and the largest difference in RTX (Lundex remission difference +5.9%, low disease activity difference +11.6%). CONCLUSION: Seropositivity was associated with increased effectiveness of non-TNFi bDMARDs, especially RTX and ABA, but not TNFis.
引用
- Courvoisier DS, Chatzidionysiou K, Mongin D, et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford). 2021. PMID: 32810263. doi:10.1093/rheumatology/keaa393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。